Clinical Trials Browser

Phase 2/3 × Adenocarcinoma × Capecitabine × Clear all

NCT01404156 2024-08-28

POWERRANGER

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms